Hepatocellular Carcinoma
Conditions
Interventions
Training and validation sets:None
Test group:None
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with Hepatitis B-related Liver Cirrhosis and Intrahepatic NHHNs: (1) Hepatitis B virus-related liver cirrhosis; (2) Newly detected intrahepatic NHHNs (<= 3 nodules) identified by EOB-MRI; (3) No history of treatment for HCC; (4) No history of other malignancies. 2. Patients with New Intrahepatic NHHNs after Achieving at Least 6 Months of Complete Response Following Local Therapy for Hepatitis B-related HCC: (1) Hepatitis B virus-related hepatocellular carcinoma (clinically or pathologically diagnosed), BCLC stage 0-B; (2) Having undergone local therapy (e.g., TACE, RFA, MWA); (3) Achieved complete response in the treated lesions for at least 6 months (according to mRECIST criteria); (4) Newly detected intrahepatic NHHNs (<= 3 nodules) identified by EOB-MRI; (5) No history of other malignancies.
Exclusion criteria
Exclusion criteria: 1. Patients with Hepatitis B-related Liver Cirrhosis and Intrahepatic NHHNs: (1) Contraindications to EOB-MRI scanning; (2) Patients with a confirmed diagnosis of hepatocellular carcinoma (HCC); (3) Poor image quality or incomplete MRI sequences; (4) Patient death or loss to follow-up. 2. Patients with New Intrahepatic NHHNs after Achieving at Least 6 Months of Complete Response Following Local Therapy for Hepatitis B-related HCC: (1) Receipt of systemic anti-tumor therapy (e.g., targeted drugs, immunotherapy); (2) Contraindications to EOB-MRI scanning; (3) Poor image quality or incomplete MRI sequences; (4) Patient death or loss to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malignant Transformation Rate;Sensitivity;Specificity;Accuracy;Area Under the Receiver Operating Characteristic Curve; | — |
Countries
China
Contacts
Public ContactPeng Huang
The Affiliated Hospital of Qingdao University
Outcome results
None listed